Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published April 2016
  • Article
  • Info & Metrics
  • PDF
Loading

Ibrutinib Disrupts CLL Tumor-Microenvironment Interactions

Niemann et al. Page 1572

Niemann and colleagues describe global changes in the CLL microenvironment during treatment with the BTK inhibitor ibrutinib. They report on changes in cytokines and chemoattractants, T-cell subsets, and activation and demonstrate disruption of tumor-macrophage interactions in the bone marrow microenvironment. This work highlights the potent effects ibrutinib exerts on both the CLL cell and the tumor-microenvironment abating the chronic inflammatory drive in this disease. Mapping of the “new” tumor-microenvironment in patients on ibrutinib may inform the design of future clinical trials.

Core Patient-Reported Outcomes in Cancer Clinical Trials

Kluetz et al. Page 1553

The FDA's Office of Hematology and Oncology Products provide their perspective on patient-reported outcome (PRO) assessment in cancer trials. The authors describe existing PRO strategies and discuss new instruments that are becoming available. They consider focusing key PRO analyses on separate measures of symptomatic adverse events, physical function, and disease-related symptoms that are important contributors to health-related quality of life. Increased rigor in PRO measurement and trial conduct are necessary, and collaboration is needed to review new and existing tools to develop a PRO strategy suitable for the needs of all those who rely on PRO to inform treatment and policy decisions.

Personalized therapies in BRAF inhibitor resistant PDX

Krepler et al. Page 1592

Krepler and colleagues analyzed patient-derived xenografts established from melanoma patients relapsed on BRAF inhibitor therapy for possible mechanisms of resistance on the genomic and protein signaling levels. By combining these two data sets, they found that, while most tumors had reactivated the BRAF pathway, a subset had also activated PI3K or MET signaling as alternative drivers. Subsequently, the PDX were expanded under chronic BRAF inhibitor drug pressure, and rational second line combination therapies targeting the escape mechanisms were shown to be effective in preclinical in vivo trials.

Nuclear Export Inhibition and Radiation in Rectal Cancer

Ferreiro-Neira et al. Page 1663

XPO1 mediates the nuclear export of critical proteins required for rectal cancer proliferation and radiation resistance. Ferreiro-Neira and colleagues evaluated the radiosensitizing effects of XPO1 inhibitor (selinexor) in preclinical models of rectal cancer. Selinexor was tested in combination with radiation fractions similar to that given in clinical practice. Combined treatment promoted nuclear survivin accumulation and subsequent depletion, resulting in increased apoptosis and enhanced radiation antitumoral effects. These findings provide a novel therapeutic option for improving radiation sensitivity in the setting of rectal cancer.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Clinical Cancer Research: 22 (7)
April 2016
Volume 22, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Clin Cancer Res April 1 2016 (22) (7) 1545;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Clin Cancer Res April 1 2016 (22) (7) 1545;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Ibrutinib Disrupts CLL Tumor-Microenvironment Interactions
    • Core Patient-Reported Outcomes in Cancer Clinical Trials
    • Personalized therapies in BRAF inhibitor resistant PDX
    • Nuclear Export Inhibition and Radiation in Rectal Cancer
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement